drugset / Trial / NCT00650104

Long-term Extension Study Evaluating Extended Release Ropinirole XL (Formerly Referred to as Ropinirole CR) in Patients Who Already Completed Either Study 167 or 164

NCT00650104

Phase 3 Completed 76 enrolled GlaxoSmithKline
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to obtain information on the long-term safety, tolerability, and therapeutic benefit of extended release ropinirole XL, and to provide a mechanism for patients who participated in either Study 167 or Study 164 to continue receiving ropinirole XL if they chose to do so.

Timeline

Start
2002-05
Primary completion
2009-03
Completion
2009-03

Drugs

EvaluationDrugModalityDoseRoute
Comparator Ropinirole Small molecule 2 mg
Comparator Ropinirole Small molecule 4 mg
Comparator Ropinirole Small molecule 6 mg
Comparator Ropinirole Small molecule 8 mg
Comparator Ropinirole Small molecule 12 mg
Comparator Ropinirole Small molecule 16 mg
Comparator Ropinirole Small molecule 20 mg
Comparator Ropinirole Small molecule 24 mg

Indications